Clinical Trials Browser

Phase 2 × INDUSTRY × Tuberous Sclerosis × Clear all

NCT05626634 2025-12-03

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Phase 2 Completed

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT03363763 2025-12-01

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Phase 2 Terminated

24 enrolled 11 charts

Erythema, Exanthema, Fibroma, Tuberous Sclerosis, Facies

NCT05059327 2025-06-04

Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

Phase 2 Completed

Seizures, Tuberous Sclerosis

NCT04285346 2023-04-04

TSC

Phase 2 Completed

23 enrolled 9 charts

Tuberous Sclerosis

NCT03650452 2021-02-18

ELEKTRA

Phase 2 Completed

141 enrolled 24 charts

CDKL5 deficiency disorder, Brain Diseases, Central Nervous System Diseases, Epilepsy, Epilepsies, Myoclonic, Nervous System Diseases, Seizures, Spasms, Infantile, Tuberous Sclerosis, Hypoxia-Ischemia, Brain, Malformations of Cortical Development, Lennox Gastaut Syndrome

NCT01690871 2013-08-02

A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

Phase 2 Withdrawn

Tuberous Sclerosis, Angiomyolipoma, Perivascular Epithelioid Cell Neoplasms